Biologics Capacity Surge: AbbVie has recently broken ground on a biologics expansion, committing to Singapore, its only Asian manufacturing presence.
🔷 Capital Outlay: US $223 million.
🔷 Scale-up: Adds a 24,000 liter single-use bioreactor capacity for drug substance.
🔷 The retrofit will let the plant pivot between antibody and small-molecule campaigns in days instead of months, accelerating tech-transfer and de-risking launches for AbbVie’s next-wave immunology and oncology pipeline.
🔷 Timeline: With construction commencing in 2024, it is anticipated that the GMP suites will go live 2026.
🔷 Total Commitment: AbbVie has invested >US $740 million in Singapore over the past decade.
PlantQuest Insight: By threading a 24 kL single-use suite into an active small-molecule campus, AbbVie is transforming its lone Asian site into a biologics workhorse without pausing current production—a feat that hinges on accurate asset registers and utility models.
At PlantQuest, we’re proud to spotlight initiatives that drive global pharmaceutical innovation. We look forward to supporting forward-thinking organisations like AbbVie as they set new benchmarks in manufacturing.
Explore our library of expert insights, tools, and resources to enhance your facility's performance and efficiency.
PlantQuest's innovative solution reduced alarm response times by up to 73% and eliminated unnecessary evacuations at a major pharmaceutical facility in Leinster, Ireland. By integrating fire system and EHS asset data into a Google Maps-like platform, the solution enhanced emergency response, minimized operational disruptions, and significantly improved financial performance.
Lorem ipsum aliquam vel justo fringillas enigma.
